ARTICLE | Distillery Therapeutics
Ophthalmic disease
October 17, 2017 4:50 PM UTC
Mouse studies suggest activating Tie2 could help treat primary open-angle glaucoma (POAG). In a mouse model of POAG, intraocular injection of a Tie2-activating antibody decreased intraocular pressure compared with a control antibody. Next steps could include testing other Tie2 activators in additional models of POAG.
Aerpio Pharmaceuticals Inc. has AKB-9778, a Tie2 activator, in Phase II testing to treat diabetic macular edema (DME), diabetic retinopathy and macular edema. ...
BCIQ Company Profiles
BCIQ Target Profiles